Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Jumps Into Growing China R&D Space

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline has joined a growing list of big pharma companies expanding in China, launching a research and development center based in Shanghai, the company announced May 24

You may also be interested in...



Emerging Markets On Executives’ Minds At JPM15

Several top executives from major multinationals made comments on emerging market strategies at the JP Morgan Healthcare Conference in San Francisco Jan. 12-15 that piqued the interest of PharmAsia News. Among them, GSK said it was looking for a broad product portfolio, Lilly noted it had doubled its sales in China and Becton Dickinson highlighted the need to develop targeted products.

Exclusive: GSK Head Of Research Due In Shanghai Thursday To Begin Detailed Audit Of China R&D Operations

In an internal email, Patrick Vallance, GlaxoSmithKline’s president for pharmaceutical R&D, says he will arrive in Shanghai June 13 to help look for answers on how a paper authored by members of GSK’s China R&D unit misrepresented data. The incident has led to the dismissal of China R&D head Jingwu Zang, who spoke to PharmAsia News about the swirling controversy.

GSK Says Paper Published In Nature Medicine By Company Scientists To Be Retracted

GSK confirms dismissal of R&D China Head Jingwu Zang. GSK internal communication seen by PharmAsia News alleges “disturbing efforts” by employees to undermine an internal investigation into a paper on preclinical research; GSK suspends programs related to IL-7 receptor signaling pathway.

Related Content

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel